» Articles » PMID: 32249902

Novel Roles of Chloroquine and Hydroxychloroquine in Graves' Orbitopathy Therapy by Targeting Orbital Fibroblasts

Overview
Specialty Endocrinology
Date 2020 Apr 7
PMID 32249902
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Graves' orbitopathy (GO) causes infiltrative exophthalmos by inducing excessive proliferation, adipogenesis, and glycosaminoglycan production in orbital fibroblasts (OFs). Interference with OF autophagy is a potential therapy for proptosis.

Objectives: Here, we aimed to evaluate the effects of chloroquine (CQ) and hydroxychloroquine (HCQ), the autophagy inhibitors commonly used in clinical practice, on OFs.

Design/setting/participants: OFs isolated from patients with GO (GO-OFs) or control individuals (non-GO-OFs) were cultured in proliferation medium (PM) or subjected to differentiation medium. OFs were treated with CQ or HCQ (0, 0.5, 2, and 10 μM), and subsequently examined in vitro.

Main Outcome Measures: CCK-8, EdU incorporation, and flow cytometry assays were used to assess cellular viability. Adipogenesis was assessed with Western blot analysis, real-time polymerase chain reaction (PCR) , and Oil Red O staining. Hyaluronan production was determined by real-time PCR and enzyme-linked immunosorbent assay. Autophagy flux was detected through red fluorescent protein (RFP)-green fluorescent protein (GFP)-LC3 fluorescence staining and Western blot analyses.

Results: CQ/HCQ halted proliferation and adipogenesis in GO-OFs in a concentration-dependent manner through blockage of autophagy, phenotypes that were not detected in non-GO-OFs. The inhibitory effect of CQ/HCQ on hyaluronan secretion of GO-OFs was also concentration dependent, mediated by downregulation of hyaluronan synthase 2 rather than hyaluronidases. Moreover, CQ (10 μM) induced GO-OF apoptosis without aggravating oxidative stress.

Conclusions: The antimalarials CQ/HCQ affect proliferation, adipogenesis, and hyaluronan generation in GO-OFs by inhibiting autophagy, providing evidence that they can be used to treat GO as autophagy inhibitors.

Citing Articles

Butyrate Ameliorates Graves' Orbitopathy Through Regulating Orbital Fibroblast Phenotypes and Gut Microbiota.

Ouyang P, Qi J, Tong B, Li Y, Cao J, Wang L Invest Ophthalmol Vis Sci. 2025; 66(3):5.

PMID: 40035727 PMC: 11892527. DOI: 10.1167/iovs.66.3.5.


Novel perspectives on the pharmacological treatment of thyroid-associated ophthalmopathy.

Li Z Front Endocrinol (Lausanne). 2025; 15:1469268.

PMID: 39872310 PMC: 11769798. DOI: 10.3389/fendo.2024.1469268.


The role of autophagy in Graves disease: knowns and unknowns.

Al-Kuraishy H, Sulaiman G, Mohammed H, Abu-Alghayth M, Albukhaty S, Jabir M Front Cell Dev Biol. 2025; 12:1480950.

PMID: 39834383 PMC: 11743935. DOI: 10.3389/fcell.2024.1480950.


The Potential of Artemisinins as Novel Treatment for Thyroid Eye Disease by Inhibiting Adipogenesis in Orbital Fibroblasts.

Guo Y, Cheng Y, Li H, Guan H, Xiao H, Li Y Invest Ophthalmol Vis Sci. 2023; 64(7):28.

PMID: 37326592 PMC: 10281061. DOI: 10.1167/iovs.64.7.28.


Autophagy in graves' ophthalmopathy.

Chen Y, Gao L, Liu Y, Shen Y, Diao J, Yang W Front Cell Dev Biol. 2023; 11:1158279.

PMID: 37123414 PMC: 10140433. DOI: 10.3389/fcell.2023.1158279.


References
1.
Potgieser P, Wiersinga W, Regensburg N, Mourits M . Some studies on the natural history of Graves' orbitopathy: increase in orbital fat is a rather late phenomenon. Eur J Endocrinol. 2015; 173(2):149-53. DOI: 10.1530/EJE-14-1140. View

2.
Ohkuma S, Poole B . Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A. 1978; 75(7):3327-31. PMC: 392768. DOI: 10.1073/pnas.75.7.3327. View

3.
Golden E, Cho H, Hofman F, Louie S, Schonthal A, Chen T . Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 2015; 38(3):E12. DOI: 10.3171/2014.12.FOCUS14748. View

4.
Li H, Yuan Y, Zhang Y, Zhang X, Gao L, Xu R . Icariin Inhibits AMPK-Dependent Autophagy and Adipogenesis in Adipocytes and in a Model of Graves' Orbitopathy . Front Physiol. 2017; 8:45. PMC: 5303717. DOI: 10.3389/fphys.2017.00045. View

5.
Furmaniak J, Sanders J, Young S, Kabelis K, Sanders P, Evans M . In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70). Auto Immun Highlights. 2015; 3(1):19-25. PMC: 4389019. DOI: 10.1007/s13317-011-0025-9. View